Table 3

Association of DNA methylation of IGFBP-2 with the odds of developing type 2 diabetes

Methylation of…OR per SD95% CI
CpGs* in the promoter region
 cg056893211.111.05, 1.17
 cg261872371.571.3, 1.9
 cg253169691.261.1, 1.45
 cg036252611.361.11, 1.66
 cg253808680.640.53, 0.78
CpGs in the gene body
 cg132202990.60.45, 0.8
 cg031495320.860.81, 0.92
  • DNA methylation of the IGFBP-2 gene in relation to type 2 diabetes risk was evaluated in a 1:1 matched case-control study (analytical sample n = 290 case subjects and n = 290 control subjects), nested within the EPIC-Potsdam cohort study. Control subjects were drawn by incidence density sampling and matched for age (±6 months), sex, fasting time (<3 h, 3 to <6 h, and ≥6 h before blood draw), time of day of blood sampling (±2 h), and season at blood sampling.

  • *CpG: DNA sequence where cytosine and guanine are connected by a single phosphate group (5′—C—phosphate—G—3′). CpG sites are subject to differential methylation. Shown are all available CpGs in the IGFBP-2 gene that were significantly differently methylated between case and control subjects after correcting for multiple testing.

  • †OR of developing type 2 diabetes associated with 1 SD higher methylation adjusted for alcohol consumption, smoking, and physical activity as well as age and sex (matching variables).